Table 3.
Effect of acetazolamide on sleep-disordered breathing
| Variable (n = 12) | Baseline | Acetazolamide |
|---|---|---|
| Total sleep time (min) | 339.8 ± 11.1 | 337.7 ± 11.0 |
| REM duration (min) | 35.0 ± 4.3 | 31.6 ± 4.1 |
| NREM duration (min) | 304.8 ± 12.3 | 306.1 ± 12.8 |
| % Sleep efficiency (TST/TIB) | 80.5 ± 2.2 | 82.6 ± 2.4 |
| % REM (TST) | 10.4 ± 1.3 | 9.4 ± 1.2 |
| % Stage 1 (TST) | 37.6 ± 2.9 | 32.3 ± 3.2 |
| % Stage 2 (TST) | 51.5 ± 2.0 | 57.9 ± 2.6* |
| % Stage 3 (TST) | 0 [0–0.2] | 0 [0–0] |
| % Stage 4 (TST) | 0 [0–0] | 0 [0–0] |
Mean overnight  (%) |
94.5 ± 0.4 | 96.0 ± 0.4* |
Lowest  (%) |
81.0 [77.5–82.8] | 83.5 [79.3–87.0] |
| Total arousal index (events h−1) | 41.1 ± 3.2 | 34.1 ± 2.7* |
| Respiratory arousal (without desaturation) | 2.7 [1.5–6.1] | 3.7 [2.0–7.2] |
| Respiratory arousal (with desaturation) | 23.2 ± 3.4 | 13.8 ± 3.3* |
| Leg movement arousals | 0.1 [0–0.4] | 0 [0–0.7] |
| Spontaneous arousal index (events h−1) | 13.6 ± 1.7 | 14.9 ± 2.1 |
| Leg movements (events h−1) | 0.4 [0–6.8] | 0.6 [0–7.8] |
Group data from the clinical PSG during the baseline and acetazolamide conditions. Data were collected in the supine posture in the absence of CPAP. Values are means ± SEM or medians [interquartile range].
*
Significant difference compared with the baseline condition.